in the serum of most patients with systemic lupus erythematosus (SLE) (Mittal et al., 1970; Terasaki et al., 1970) . They appear to be equally cytotoxic for autologous and heterologous lymphocytes (Stastny and Ziff, 1971) . Studies of the nature of these antibodies showed that their cytotoxic effect is temperature-dependent and maximal at 15°C, that their immunoglobulin class is IgM, and that they are equally reactive with T and B lymphocytes (Winfield et al., 1975a) . Studies of the clinical significance of cold-reactive lymphocytotoxic antibodies in SLE have shown a consistent association with neuropsychiatric complications (Butler et al., 1972; Bluestein and Zvaifier, 1976; Bresnihan et al., 1977b) . In other respects, however, clinical studies have been inconclusive, which may partly be related to the retrospective nature of most series. Previous studies have suggested an association between cold-reactive lymphocytotoxic antibodies and lymphopenia (Winfield et al., 1975b; Utsinger, 1976) . A detailed prospective clinical analysis of SLE began at Hammersmith Hospital in 1973. In all, 50 patients have been investigated, and their clinical features have been described elsewhere (Grigor et al., 1978) . This report relates the clinical features in these patients to the presence of lymphocytotoxic antibodies.
Patients and methods
Fifty successive patients with SLE, seen at Hammersmith Hospital between 1973 and 1977, were intensively investigated during at least one hospital admission and subsequently followed as outpatients.
A strict study protocol had been designed which included a large number of serological and noninvasive investigative procedures (Grigor et al., 1978) .
LYMPHOCYTOTOXIC ANTIBODY ASSAY
Serum was obtained at each hospital visit and stored in aliquots at -20C until the time of testing. The two-stage microdroplet dye exclusion cytotoxicity assay was used (Mittal et al., 1968) . Target lymphocytes from at least 20 of a panel of 27 normal subjects were used to test each serum sample. All incubations were at 15°C. Fresh rabbit serum was used as a source of complement. The degree of cytotoxicity was assessed independently by two observers using phase-contrast microscopy and without knowledge of which serum was being tested. (Pincus et al., 1969) . 14C-DNA was obtained from the Radiochemical Centre, Amersham. C3 concentrations were measured by radial immunodiffusion in agar (Kohler et al., 1967 maximum cytotoxicity index of the 21 patients who at some time developed evidence of CNS involvement was 5.4 ± 2.1, compared with 3.1 ± 1.4 in those patients who remained free of neuropsychiatric disease. This difference was statistically significant (P < 0.001). Similarly, there was a significant difference (P < 0.004) between the mean cytotoxicity index of those who developed cutaneous manifestations (4.4 ± 2-1) and those who did not (2.3 ± 1P0).
There was no statistical difference between the indices of those who had, or had not, other major manifestations.
There was considerable fluctuation in the degree of cytotoxicity in individual patients throughout the study. However, there was no association between the changes in lymphocytotoxicity and the appearance of disease exacerbations. Indeed, in some patients the maximum cytotoxicity coincided with periods of apparent remission. Furthermore, the degree of lymphocytotoxicity was not noticeably altered by corticosteroid therapy. This is shown in Fig. 1 , which compares the mean cytotoxicity (± SD) of sera obtained from groups of patients taking various doses of prednisone or none. The lymphocytotoxicity was similar in each group and there was a considerable degree of overlap.
HAEMATOLOGICAL FEATURES
It was possible to compare lymphocyte counts with the lymphocytotoxicity of 114 sera. This figure excludes sera obtained from patients receiving cytotoxic agents such as cyclophosphamide or azathioprine. The results are shown in Fig. 2 . No association between lymphopenia and the degree of lymphocytotoxicity was seen. Thus the lymphocytotoxicity of sera obtained from patients with severe lymphopenia (< 750/mm3) was not different from patients with either moderate lymphopenia (750-1500/mm3) or normal lymphocyte counts (> 1500/mm3). Furthermore, there was no association between lymphocytotoxicity and anaemia, leucopenia, or thrombocytopenia. 
SEROLOGICAL FEATURES
Comparison between lymphocytotoxicity and DNAbinding values was possible in 315 sera, and with C3 concentrations in 215 sera. Sera with normal DNAbinding values (< 30%) tended to be less cytotoxic than sera with raised DNA-binding values (Fig. 3) these manifestations. This finding is in agreement with others (Butler et al., 1972; Bluestein and Zvaifler, 1976) . These results, in association with the observation that lymphocytotoxic antibodies from patients who have neuropsychiatric symptoms crossreact with human brain (Bresnihan et al., 1977b) , strongly suggest a possible pathogenic role in cerebral lupus. Our study suggests that of the other clinical manifestations only cutaneous lesions correlate with lymphocytotoxicity. Serological evidence of disease activity, as represented by DNA-binding values and C3 concentrations, does not appear to correlate with the lymphocytotoxicity of individual sera.
An association between lymphopenia and the presence of lymphocytotoxic antibodies has been previously reported (Winfield et al., 1975a; Utsinger, 1976) . This observation was not supported by our study. It should be noted that our lymphocytotoxicity assays were performed at 15°C using undiluted serum samples. Assays performed under similar conditions by Winfield et al. (1975a) also failed to show an association with lymphopenia. When they used undiluted serum samples they found an association with lymphopenia only when assays were performed at 25°C, suggesting the possibility that a distinct subpopulation of antilymphocyte antibodies may be cytotoxic at higher temperatures. Previously, these authors had demonstrated that the predominant cold-reactive antilymphocyte antibody in SLE was maximally cytotoxic at 15°C and that the activity rapidly declined at higher temperatures (Winfield et al., 1975b) . Utsinger (1976) reported an inverse linear correlation between serum cytotoxicity measured at 15°C and peripheral blood lymphocyte counts. However, this correlation was made with a relatively small number (50) of matched samples and the degree of lymphopenia was modest (all greater than 750/mm3). Others have observed associations between lymphocytotoxic antibodies and various other haematological disorders, such as haemolytic anaemia or thrombocytopenia, or both (Bluestein and Zvaifler, 1976) , and leucopenia (Butler et al., 1972) , but not specifically with lymphopenia. Again, these observations were not confirmed by us. It would indeed be surprising if an antibody whose cytotoxic capacity was so temperature-dependent could lead to substantial cell lysis at physiological temperatures. Clearly, other antibodies with different physical requirements may yet be incriminated in the lymphopenia of SLE.
The in-vivo action of cold-reactive lymphocytotoxic antibodies on lymphocyte function remains unclear,. spontaneously occurring thymocytotoxic antibody tppears in New Zealand mice (Shirai and Mellors, 1972) , and it has been suggested that this antibody may result in altered lymphocyte function, particularly impaired suppressor lymphocyte function (Gelfand and Steinberg, 1973) . Wernet and Kunkel (1973) The possibility that lymphocytotoxic antibodies cross-react with other tissue antigens and thereby mediate tissue injury has also been suggested. In this way reactivity with human brain antigens may result in cerebral manifestations (Bluestein and Zvaifler, 1976; Bresnihan et al., 1977b) . In addition, crossreactivity with trophoblast-reactive lymphocytotoxic antibodies in SLE patients having spontaneous abortions suggested a possible role for these antibodies in the high spontaneous abortion rate (Bresnihan et al., 1977a) . The demonstration of cross-reactivity with fetal erythrocytes but not adult erythrocytes suggested that cold-reactive lymphocytotoxic antibodies may share certain characteristics with cold agglutinins, such as specificity for i antigen (Goldberg et al., 1978) . Possibly, therefore, lymphocytotoxicity is a feature common to many antibodies whose primary specificity is for antigens present on several different tissues. As suggested by our study, lymphocytotoxicity mediated by coldreactive antilymphocyte antibodies may never occur in vivo. The pathogenic effects of lymphocytotoxic antibodies may arise through reactions with other tissues. We thank Miss Mary Oliver for her expert technical help. This work was supported by a grant from the Arthritis and Rheumatism Council and the Wellcome Trust.
